HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

Building a 3D Cancer Atlas with AI

Several cancer research organizations and Owkin, a company specializing in artificial intelligence (AI) are collaborating to map cancer cell interactions with MOSAIC, a new AI project. The project aims to reach near-single cell resolution using a spatial omics, which includes data mapping spatial […]

more info 06/07/2023View Related Articles
Bookmark and Share

Bringing Allogeneic Cell Therapies to More Patients

Allogeneic (allo) cell therapies offer substantial benefits to patients due to their efficacy and availability. However, giving patients access to these treatments presents obstacles at the manufacturing level. Donor screening and recruiting is key to the process of building a sufficient supply […]

more info 06/07/2023View Related Articles
Bookmark and Share

Three Strategies for Providers Implementing Value-Based Care

Value-based care models have been put forward as a solution for rising Medicare costs, paying providers for the value their care provides patients. New laws are further incentivizing adaptation of these payment models. To jump on board successfully, Edifecs published an article earlier this year […]

more info 06/07/2023View Related Articles
Bookmark and Share

AI Medtech is Finally Living Up to its Potential

Artificial intelligence (AI) and machine learning (ML) has seen increasing implantation into medtech solutions in recent years, driven by advances in the field. AI technology is currently assisting in surgeries, imaging analysis, and payer decision-making. In a new Med Device Online article, learn […]

more info 06/07/2023View Related Articles
Bookmark and Share

GSK’s RSV Vaccine Nabs First EU Approval of its Kind

Glaxo-Smith Klein (GSK) has received approval by the European Commission for its respiratory syncytial virus (RSV) vaccine Arexvy in adults aged 60 and up. This marks the first EU approval of a vaccine for RSV vaccine. This puts them ahead of Pfizer, whose vaccine Abrysvo has yet to be approved in […]

more info 06/07/2023View Related Articles
Bookmark and Share

PBM Industry Pushes Back Against Pharma Lobbyists

Amid growing scrutiny of pharmacy benefit managers (PBMs) at the public and congressional level, a PBM industry group has launched an ad campaign pointing the blame back at pharma for high drug prices. The group argues that the pharmaceutical industry has spent millions of dollars on advertising and […]

more info 06/06/2023View Related Articles
Bookmark and Share

Building an Effective Real-World Evidence Strategy

Real-world evidence (RWE) is a key part of a successful product launch or indication expansion, but doing so requires a careful strategy to maximize efficiency and minimize costs. In a new article by Richard Hallquist of IQVIA, learn about how to build an evidence strategy that maximizes the odds of […]

more info 06/06/2023View Related Articles
Bookmark and Share

Medicare Drug Price Negotiations Will Include Patient Perspectives and Real-World Evidence

According to Medicare Director Meena Seshamani, upcoming drug pricing negotiations will take the patient perspective and real-world evidence (RWE) into account. The agency wants to incorporate information about how high prices of key therapeutics impacts patients, as well as how the drugs are used […]

more info 06/06/2023View Related Articles
Bookmark and Share

A Look at How Medicare Advantage Affects Providers

Although Medicare Advantage (MA) has been greatly beneficial for participating payer organizations, the picture is less rosy for providers, according to an analysis from the Kaiser Family Foundation (KFF). Providers must deal with a more complex policy framework when working with MA plans, resulting […]

more info 06/06/2023View Related Articles
Bookmark and Share

First Lawsuit Against US Medicare Drug Pricing Negotiations Filed by Merck

The pharma giant Merck & Co has filed a lawsuit against the US government over upcoming Medicare drug pricing negotiations included in the Inflation Reduction Act passed last year. The company argues that the negotiations would violate their 5th Amendment rights by forcing them to provide drugs […]

more info 06/06/2023View Related Articles
Bookmark and Share

AstraZeneca Looking Toward Early Full Approval for Anticoagulant Reversal Medication

Following positive results in a phase IV clinical trial, Astrazeneca is making moves to apply for full approval for its anticoagulant reversal drug Andexxa earlier than expected. Data from the trial, which is being ended early based on outside recommendations, showed that the drug was effective in […]

more info 06/05/2023View Related Articles
Bookmark and Share

Inflation Reduction Act R&D Cost Request May Prove Problematic

The US Inflation Reduction Act requires drugmakers to justify new drug prices based on the R&D costs needed to develop a therapeutic during drug pricing negotiations. However, this policy may be short-sighted, according to some experts, as it doesn’t account for the lost investments in failed […]

more info 06/05/2023View Related Articles
Bookmark and Share

Bristol Myers Squibb’s Heart Medication Camzyos Receives NICE Recommendation

Bristol Myers Squibb (BMS) has received a recommendation for approval from the UK’s National Institute for Health and Care Excellence (NICE) for its heart drug Camzyos (mavacamten). The recommendation covers the use of the drug as a adjunct treatment for symtompatic obstructive hypertrophic […]

more info 06/05/2023View Related Articles
Bookmark and Share

Real-World Data Study Finds Two Year Immunotherapy Regimens Appropriate for Advanced Lung Cancer

A real-world data (RWD) study published in JAMA Oncology finds that administering immunotherapy to patients with advanced non-small cell lung cancer (NSCLC) is appropriate. The study, which followed 1091 patients at Penn Medicine’s Abramson Cancer Center, found that patients whose cancer hasn’t […]

more info 06/05/2023View Related Articles
Bookmark and Share

CMS Drug Price Negotiations Complicated by Therapeutic Alternatives Clause

As part of the upcoming drug pricing negotiations from the Inflation Reduction Act, drugmakers will need to justify high US drug prices by comparing efficacy and value with therapeutic alternatives. The problem, according to industry leaders, is that the definition of therapeutic alternatives is […]

more info 06/05/2023View Related Articles
Bookmark and Share

EMA Calls for Novartis’ Sickle Cell Treatment to Lose Market Authorization

  Novartis took a hit this week as the European Medicines Agency (EMA) has recommended that its market authorization for Adakveo, a sickle cell medication, be revoked. Although initial data suggested the drug could help reduce pain crises in patients 16 and older, the agency argues that […]

more info 06/02/2023View Related Articles
Bookmark and Share

Better Employee Health Through Specialty Rx Carve-Outs

Specialty Rx carve-outs allow for dedicated management of high-cost specialty medications by bypassing traditional pharmacy benefit managers (PBMs). Doing so, according to a new article in Corporate Wellness Magazine, can help improve employee health by applying specialized expertise to coverage […]

more info 06/02/2023View Related Articles
Bookmark and Share

Using Real-World Evidence to Accelerate Medical Device Development

Korea’s Ministry of Food and Drug Safety is now accepting real-world evidence (RWE) as clinical data for medical device approval decision-making. This opens up a pathway for medical device manufacturers to accelerate development with real-world data (RWD) resources like clinical data from devices, […]

more info 06/02/2023View Related Articles
Bookmark and Share

Working with Pharma to Advance NHS Health Equity Efforts

A key priority in the UK’s National Health Service (NHS) Operational Planning Guidance 2023/2024 is improving health outcomes for the poorest 20% of patients in the nation. Partnerships between NHS systems and the pharmaceutical industry represent one way to help address health disparities. Doing […]

more info 06/02/2023View Related Articles
Bookmark and Share

Targeting Health Equity at the Neighborhood-Level

overhead view of a neighborhood

A person’s living environment is an important social determinant of health (SODH), affecting access to care and employment, exposure to environmental hazards, and financial pressures. As a result, health equity efforts need to zoom down to the neighborhood level to improve health outcomes. In a new […]

more info 06/02/2023View Related Articles
Bookmark and Share

Molecular Templates’ Multiple Myeloma Trial Partial Hold Lifted

Molecular Templates’ clinical trial for MT-0169, its experimental multiple myeloma therapeutic, is back on, following the US Food and Drug Administration (FDA) lifting a partial hold. The hold was placed on the trial following two adverse events experienced by patients, who both recovered. The move […]

more info 06/01/2023View Related Articles
Bookmark and Share

Addressing Barriers to Care in Rural America

Rural US residents face significant barriers to care that significantly worsen health outcomes. Addressing these barriers is a complex task due to the underlying reasons behind them. In a new Becker’s Hospital Review article, Karen Joynt-Maddox, MD, MPH, associate professor at the Washington […]

more info 06/01/2023View Related Articles
Bookmark and Share

Pfizer’s RSV Vaccine Gets FDA Approval

The US Food and Drug Administration (FDA) has given approval for the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in older adults. The move comes shortly after the agency approved another RSV vaccine from GSK. This sets up a marketplace standoff between the two, competing over a market […]

more info 06/01/2023View Related Articles
Bookmark and Share

Over 500,000 Disenrolled from Medicaid After COVID-19 PHE Ends

Shortly following the end of the COVID-19 public health emergency, pandemic-era restrictions on Medicaid redetermination ended. In that time, over 500,000 people have been disenrolled, interrupting their coverage and impacting their access to healthcare. Some states have kicked off more […]

more info 06/01/2023View Related Articles
Bookmark and Share

CMS Opens Up Coverage of Alzheimer’s Drugs

Once Lequembi, Easai’s amyloid-targeting Alzheimer's drug, is potentially approved by the US Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS) have announced they will expand coverage for the class of drugs. Previously, CMS only covered amyloid therapies in […]

more info 06/01/2023View Related Articles
Bookmark and Share

US Congressional Research Service Asks When Pharma Can Challenge Drug Pricing Reform

The Congressional Research Service (CRS), a nonpartisan public policy research institute, released a report asking for more clarity on when lawsuits over upcoming Medicare drug pricing reform can commence. The report comes as industry groups also seek more transparency on time windows as they […]

more info 05/31/2023View Related Articles
Bookmark and Share

Incorporating Value-Based Care into Nursing Homes with the Payvider Model

As nursing homes increasingly look for ways to incorporate value-based care into their practices, some are moving towards payvider models, wherein they partner with a Medicare Advantage insurer and play the roles of payer and provider together. A panel of experts spoke about this strategy in a […]

more info 05/31/2023View Related Articles
Bookmark and Share

Eli Lilly Reaches $13.5 Million Settlement in Insulin Pricing Case

Eli Lilly has settled a case with patients using insulin, who accused the company and others of artificially inflating prices of the lifesaving drug. Lilly will pay out a total of $13.5 million and will maintain their $35 a month out-of-pocket price cap for four years at minimum. The company, which […]

more info 05/31/2023View Related Articles
Bookmark and Share

Canadian Health Officials Tried to Hide Evidence Health Minister Stalled Drug Pricing Reform

Recently released emails show that Health Canada officials tried to hide a letter from Health Minister Jean-Yves Duclos to the Patented Medicines Prices Review Board (PMPRB), Canada’s independent drug pricing agency, asking them to delay drug pricing reform last year. The letter mirrored the pharma […]

more info 05/31/2023View Related Articles
Bookmark and Share

Real World Data Study Finds Comprehensive Genomic Profiling Improves Cancer Outcomees

Real-world data (RWD) to be presented at this year’s upcoming American Society of Clinical Oncology’s Annual Meeting shows that comprehensive genomic profiling (CGP) improves cancer patients’ outcomes. The study, which covered 1,423 advanced cancer patients who received CGP from 2019 to 2021, showed […]

more info 05/31/2023View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • …
  • 221
  • Next Page

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

    No feed items found.

 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists